Status:
UNKNOWN
Concurrent Xeloda and Radiotherapy for Bone Metastases
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Solid Tumors
Bone Metastases
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Hypothesis: Radiosensitization using Xeloda should improve the rate of complete pain relief. Primary Objective: * To determine the frequency of pain relief for the proposed regimen. Secondary Objec...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- The patient must be 18 years of age or older.
- The patient must have epithelial malignancy.
- Radiographic evidence of bone metastasis is required. Acceptable studies include plain radiographs, radionuclide bone scans, computed tomography scans and magnetic resonance imaging.
- The patient must have pain that appears to be related to the radiographically documented metastasis.
- Patients must have an estimated life expectancy of 3 months or greater.
- Signed study-specific informed consent.
- Karnofsky performance status 40.
- Calculated creatinine clearance \> 50 ml/min
Exclusion
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00192777
Start Date
November 1 2004
Last Update
October 8 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rambam Health Care Campus
Haifa, Israel, 31096